ARTICLE | Clinical News
UroVysion bladder cancer assay regulatory update
December 4, 2000 8:00 AM UTC
VYSI submitted a 510(k) application to the FDA for marketing approval of its UroVysion fluorescent DNA probe assay to monitor the recurrence of bladder cancer by detecting chromosomal abnormalities in...